

# BIBLIOGRAFIA

---

1. Marco Garbayo, José Luis et al. “Cross-sectional analysis of retrospective case series of hospitalisations for gastropathy caused by non-steroidal anti-inflammatory treatment; risk factors and gastroprotection use.” European journal of hospital pharmacy: science and practice vol. 24,6 (2017) 355-360.
2. Shabani D, Murtezani A, Tahirbegolli B, Junku- Shkololli A, Ibraimi Z. Non-steroidal anti-inflammatory drugs and gastroprotection in primary health care users. Med Pharm Rep. 2020;93(3):246-252.
3. Kanno T, Moayyedi P. Who Needs Gastroprotection in 2020? Curr Treat Options Gastroenterol. 2020 Nov 11:1-17
4. Targowik LE, Metge CJ, Lemung S, et al. The relative efficiencies of gastroprotective strategies in chronic users of nonsteroidal antiinflammatory drugs. Gastroenterology 2008; 134(4):937-944
5. Maneesh Gupta, MD, Glenn M. Eisen, MD, MPH Division of Gastroenterology, Digestive Health Center, Center for Health and Healing, Portland, USA. NSAIDs and Gastrointestinal Tract, Current Gastroenterology Reports 2009;11:345-353
6. Niestandardowe leki przeciwzapalne a przewód pokarmowy vol.19/nr1/styczeń 2010 Medycyna po Dyplomie, Komentarz: Prof. dr hab. med. Andrzej Dąbrowski
7. Konturek SJ, Konturek PC, Brzozowski T. Prostaglandins and ulcer healing. J Physiol Pharmacol. 2005 Sep;56 Suppl 5:5-31. PIMD: 16247187

